Association of Target Volume Margins With Locoregional Control and Acute Toxicities for Non-small cell lung cancer Treated With Concurrent Chemoradiation Therapy

Yegya-Raman, Nikhil; Reyhan, Meral; Kim, Sinae; Deek, Matthew P.; Yue, Ning J.; Zou, W.; Malhotra, Jyoti; Aisner, Joseph; Jabbour, Salma K.

doi:10.1016/j.prro.2018.08.007

Cited by 9 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The radiation treatment planning including details regarding simulation, immobilization, target volumes, and dose constraints were consistent with our institution's standardized approach for patients with lung cancer. 16 Contouring was performed in Eclipse (Varian Medical Systems, Palo Alto, CA), the tumor was delineated by the physician, and lung tissue was determined by the clinical segmentation wizard and reviewed by the physician. Treatment planning was performed in Eclipse using the Anisotropic Analytical Algorithm (version 11.0-15.6) with 6 MV, 10 MV, or 15 MV treatment energies depending on the patient habitus.…”

Section: Methodsmentioning

confidence: 99%

Adaptive Lung Radiation Therapy in the Era of Immunotherapy: A Single-Center Retrospective Study

Portal

Piperdi

et al. 2024

Advances in Radiation Oncology

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Adaptive Lung Radiation Therapy in the Era of Immunotherapy: A Single-Center Retrospective Study

Portal

Piperdi

et al. 2024

Advances in Radiation Oncology

Self Cite

View full text Add to dashboard Cite

“…SBRT combines the conformality of IMRT with robust immobilization methods to ablate lesions with millimeter accuracy inside the body. This may allow ablation of metastatic lesions or retreatment of measurable disease in previously radiated fields safely [ 34 ]. SBRT combined with best systemic therapy for measurable disease recurrence may allow for optimal treatment of recurrent disease or delaying of initiation of systemic therapy.…”

Section: New Technology In Radiation Oncologymentioning

confidence: 99%

Treatment of node-positive endometrial cancer: chemotherapy, radiation, immunotherapy, and targeted therapy

Tubridy,

Taunk,

2024

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion StatementThe standard of treatment for node-positive endometrial cancer (FIGO Stage IIIC) in North America has been systemic therapy with or without additional external beam radiation therapy (RT) given as pelvic or extended field RT. However, this treatment paradigm is rapidly evolving with improvements in systemic chemotherapy, the emergence of targeted therapies, and improved molecular characterization of these tumors. The biggest question facing providers regarding management of stage IIIC endometrial cancer at this time is: what is the best management strategy to use with regard to combinations of cytotoxic chemotherapy, immunotherapy, other targeted therapeutics, and radiation that will maximize clinical benefit and minimize toxicities for the best patient outcomes? While clinicians await the results of ongoing clinical trials regarding combined immunotherapy/RT as well as management based on molecular classification, we must make decisions regarding the best treatment combinations for our patients. Based on the available literature, we are offering stage IIIC patients without measurable disease postoperatively both adjuvant chemotherapy and IMRT with carboplatin, paclitaxel, and with or without pembrolizumab/dostarlimab as primary adjuvant therapy. Patients with measurable disease post operatively, high risk histologies, or stage IV disease receive chemoimmunotherapy, and vaginal brachytherapy is added for those with uterine risk factors for vaginal recurrence. In the setting of endometrioid EC recurrence more than 6 months after treatment, patients with pelvic nodal and vaginal recurrence are offered IMRT and brachytherapy without chemotherapy. For measurable recurrence not suitable for pelvic radiation alone, chemoimmunotherapy is preferred as standard of care.

show abstract

Dosimetric comparison of free-breathing versus respiratory motion-managed radiotherapy via four-dimensional computed tomography-based volumetric-modulated arctherapy for lung cancer

Sarihan,

Tunc,

Kahraman

et al. 2023

Cancer/Radiothérapie

View full text Add to dashboard Cite

Association of Target Volume Margins With Locoregional Control and Acute Toxicities for Non-small cell lung cancer Treated With Concurrent Chemoradiation Therapy

Abstract: Smaller margins were used for larger tumors but were not associated with an increase in locoregional failures. Additional studies could clarify whether smaller margins, when used alongside modern radiation therapy techniques, decrease treatment-related toxicity for inoperable NSCLC.

Cited by 9 publications

References 21 publications

Adaptive Lung Radiation Therapy in the Era of Immunotherapy: A Single-Center Retrospective Study

Adaptive Lung Radiation Therapy in the Era of Immunotherapy: A Single-Center Retrospective Study

Treatment of node-positive endometrial cancer: chemotherapy, radiation, immunotherapy, and targeted therapy

Dosimetric comparison of free-breathing versus respiratory motion-managed radiotherapy via four-dimensional computed tomography-based volumetric-modulated arctherapy for lung cancer

Contact Info

Product

Resources

About